Go to https://doi.org/10.3390/ijms232315250

1. Introduction

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, inflammatory skin disease of inverse body regions. HS is a globally underestimated disease with a prevalence of 0.4–1% ^[1][2]. Some data describe a prevalence of 4% ^[3]. The disease is accompanied by inflammatory nodules, abscesses, scars, contractures, and fistulas that significantly reduce the patient’s quality of life. Therapy of HS consists of local antiseptics, local antibiotics, systemic antibiotics, high-dose zinc therapy, biologics, and surgical interventions ^[4]. In advanced disease with many fistulas, surgery and combined immunomodulatory therapies can be indicated. In some cases, preoperative downstaging with antibiotics may be useful. There is currently no curative therapy as the pathogenesis is not yet fully understood. According to current knowledge, the pathogenesis of HS is multifactorial. HS is associated with smoking, obesity, and metabolic syndrome. Use of hormonal drugs for treatment of HS is discussed in the literature. In some cases, taking medications such as spironolactone, which also have an anti-hormonal effect, leads to an improvement in HS ^[5][6].

The hormonal role in the pathogenesis of HS is not yet fully understood. A worsening of HS is often described by patients premenstrually and after pregnancy ^[7]. Therefore, a hormonal change could be a cause of HS. Many patients with HS have impaired glucose tolerance and insulin resistance. There are some case control studies describing an improvement in HS under antidiabetic or antiandrogenic therapy. The aim of this work is to summarize the current knowledge regarding hormones and their possible role in the molecular pathomechanisms of HS.

2. HS Methods

In this work, a systematic review has been conducted for articles on PubMed, MEDLINE, and Web of Science databases published between 1985 and 2022. This work has been conducted according to the PRISMA criteria ^[8]. The main focus of this research was on recent data of the last five years. Only articles in English and German have been included in this review. The flow chart with the research strategy can be seen in Figure 1. Meta-analyses, randomized double-blind trials, experimental studies, case-control studies, cross-sectional studies, and retrospective chart reviews were included for the review. Recent case reports about hormones have also been mentioned in this review so that new trends can be considered. Reviews, abstracts, and letters to the editor were not included. The screening for suitability and selection of the records has been carried out by two persons. In case of disagreement about inclusion, a third person was consulted. The following search terms were used: (“hidradenitis suppurativa” OR “acne inversa”) AND (“hormones” OR “hormone” OR “pregnancy” OR “menstruation” OR “menopause” OR “puberty” OR “finasteride” OR “spironolactone” OR “flutamide” OR “CPA” OR “cyproterone acetate “ OR “metformin” OR “insulin resistance” OR “insulin” OR “IGF-1” OR “insulin-like-growth-factor-I” OR “somatomedin-C” OR “HOMA-IR” OR “glucose metabolism” OR “pancreas” OR “beta cells” OR “adipocytes” OR “adipokine” OR “visfatin” OR “resistin” OR “leptin” OR “RBP4” OR “Retinol binding protein 4” OR “adiponectin” OR “omentin-1” OR “metabolic syndrome” OR “obesity” OR “diabetes” OR “weight loss” OR “bariatric surgery” OR “antidiabetic” OR “endocrinology” OR “endocrine” OR “PCOS” OR “polycystic ovary syndrome” OR “thyroid function” OR “thyroid” OR “antiandrogens” OR “sexual hormones” OR “androgens” OR “androgen” OR “testosterone” OR “estrogen” OR “progesterone” OR “LH” OR “FSH” OR “trigger factors” OR “pituitary gland” OR “hypothalamus” OR “pituitary-hypothalamus axis” OR “hormonal balance”). Included articles were screened for suitability based on the title and abstract. Subsequently, the original data and information of the full texts were evaluated. The references of identified records have been used to expand the search. In addition, we searched for current clinical trials in the library clinical trials using the keyword HS.

Figure 1. Flowchart with the research strategy in this systematic review.

3.anifestation and RExacesultsrbation

In this systematic review, 42 articles have been included. The included articles dealt with “HS manifestation and exacerbation” (7%), “sexual hormones” (14%), “anti-androgen therapy” (29%), “thyroid function” (21%), “polycystic ovary syndrome” (5%), and “insulin resistance and adipokines” (24%). Clinical response has been assessed using Hidradenitis Suppurativa Physician’s Global Assessment (HS-PGA), Hurley system, Dermatology Life Quality Index (DLQI) ^[9], or/and International Hidradenitis Shormonal influppurativa Severity Score System (IHS4) ^[10] in the studies.

3.1. HS Manifestation and Exacerbation

The hormonal influence on HS is evident in the typical fluctuations of the disease. HS usually begins peripubertally and shows exacerbation after pregnancy (Table 1). Detailed analysis of the timing from the fluctuations could provide further insight into HS pathogenesis. Perimenstrually, 43–76.7% of patients report subjective worsening in HS ^[7][11]. A meta-analysis has shown that about 25% of the patients report improvement and 20% of the patients report worsening in HS during pregnancy ^[12]. However, about 60% of the patients show worsening in HS postpartum ^[12]. All these results support the hormonal influence in HS.

Table 1. Current findings about HS manifestation and exacerbation. 

3. Sexual Hormones in HS

3.2. Sexual Hormones

It has long been suspected that pathophysiology of HS is linked to sex hormones. Sex hormones are steroid hormones that are produced in the gonads, placenta, or adrenal cortex. Hormones are especially important for human reproduction and formation of the sex. The release is controlled by the hypothalamic-–pituitary axis. The male sex hormones include androgens and female sex hormones include estrogens, gestagens, and hCG. The connection between HS and sex hormones is obvious, but, so far, the exact connection could be not clarified. HS shows clinical deterioration or improvement at certain times, characterized by hormonal fluctuations. During pregnancy, clinical improvement may occur in HS. The frequent peripubertal onset of HS and perimenstrual flares suggest that sex hormones are involved in HS pathogenesis (Table 2).

In an experimental study, immunohistochemical expression of the androgen receptor (AR) and estrogen receptor (ER) in HS skin tunnels has been investigated ^[13]. HS showed increased AR expression in the infundibulum and skin tunnel compared to healthy skin. AR expression was higher in males than in females. Immunohistochemical ER expression was predominantly negative. In a microarray analysis of gene expression, HS lesions showed increased androgen receptor (AR) transcriptional activity compared to non-lesional skin ^[14]]. Apocrine glands in HS show no difference in AR and ER receptor expression ^[15]. Zouboulis’ study also showed a subordinate role of the apocrine gland in HS ^[16]. Interestingly, androgen-controlled genes were up-regulated in women, while genes affecting fat metabolism were down-regulated in men ^[16]. Mortimer et al. discovered early on that female HS patients have an elevated testosterone and free androgen index ^[17]]. There are three cases reported where cross-sex hormone therapy (CSHT) with testosterone resulted in an exacerbation or manifestation of HS ^[18][19]. In contrast to the above results, Harrison reports that there is no difference in testosterone between HS and healthy controls [20]. After stimulation by thyrotropin-releasing hormone and gonadotropin-releasing hormone, increased values were found for prolactin and TSH ^[20]. This is remarkable as usually the response to TRH testing is blunted in males compared to women ^[21][22]. Harrison et al. concluded that there might rather be a disturbance in the feedback signals of the peripheral hormones in HS. There are no recent data on the hypothalamic–pituitary axis. The available data on antiandrogenic therapy in HS are analyzed in the next chapter.

Table 2. Current findings about sexual hormones in HS.

3.3. Anti-Androgen Therapy

4 Anti-Androgen Therapy in HS

The efficacy of different drugs with an anti-androgenic effect further supports the role of hormones in HS (Table 3-5). Clinical improvement has been observed in female HS patients with the use of antiandrogenic drugs. In this paper, anti-androgenic drugs finasteride, spironolactone, and cyproterone acetate have been analyzed in HS.

In a retrospective study by Kraft et al., 64 female patients with HS were included. Antiandrogenic therapy was more effective compared to antibiotic therapy (55% vs. 26%; p < 0.04) ^[23]. These positive results were included in the 2019 North American guideline for HS. They recommend use of hormonal agents in appropriate patients and mild to moderate HS ^[24]. Estrogen-containing oral contraceptives, spironolactone, cyproterone acetate, metformin, finasteride, and flutamide should be used in combination with other agents ^[24].

There are some case series that show a positive effect of finasteride in HS ^{[25][26][27][28]}. Finasteride is a competitive inhibitor of steroid 5α-reductase and has an anti-androgenic effect. Conversion of testosterone into dihydrotestosterone (DHT) is selectively inhibited by finasteride. DHT is the biologically active form of testosterone. Testosterone circulates in blood and enters the cell through lipophilic character ^[29]. Within the cell, it is converted into DHT. DHT and the intracellular androgen receptor form a hormone–receptor complex that migrates into the cell nucleus and binds to a hormone-responsive element (HRE) ^[29]. This interaction thus influences gene expression. In Germany and the USA, finasteride is approved in a daily dose of 1 mg for androgenic alopecia and 5 mg for benign prostatic hyperplasia ^[30]. In all four reports, the patients showed a significant improvement in HS ^{[25][26][27][28]}. Under therapy with finasteride, there was a decrease in frequency and intensity of HS relapses. In some patients, use of finasteride resulted in complete healing of lesions. In most cases, a daily dose of 5 mg was used and well-tolerated by the patients. In rare cases, headache, nausea, menstrual irregularities, breast tenderness, or decreased libido/sexual function have been described as adverse events ^[27]. It should be noted that all case series reported predominantly about female patients, so adverse events could be significantly more severe in male patients ^[31]. Overall, finasteride appears to be a safe and effective treatment option for HS.

Table 3. The use of finasteride (antiandrogen therapy, inhibitor of steroid 5α-reductase) in HS.

In recent years, use of spironolactone in young female patients has increased significantly ^[32]. In the age group of 13 to 19 years, its usage has increased three times compared to previous years ^[32][33]. Spironolactone is a competitive aldosterone receptor antagonist and has weak antiandrogenic, estrogenic, and glucocorticoid effects. Spironolactone is a potassium-sparing diuretic and is licensed for treatment of severe heart failure, resistant hypertension, nephrotic syndrome, liver cirrhosis, and Conn’s syndrome ^[34]. The response to spironolactone in HS ranges from 42 to 85% ^[5][35]. There was no difference between monotherapy with spironolactone and combination with other drugs ^[36]. Spironolactone can be administered in a dose of 25 to 200 mg ^{[5][6][35][37]}. A daily dose of 100 mg has been administered most frequently. All reports of antiandrogenic therapy with spironolactone in HS are from female patients. Spironolactone also has a positive effect on quality of life ^[37]. A randomized phase 4 trial was designed to investigate the efficacy and optimal dose of spironolactone in HS (ClinicalTrials.gov Identifier: NCT04100083). The study was discontinued due to lack of funding.

Table 4. Use of spironolactone (antiandrogen therapy, aldosterone antagonist) in HS.

One of the first hormonal drugs used in HS is cyproterone acetate (CPA). CPA is a competitive antagonist at the androgen receptor and agonist at the progesterone receptor. CPA prevents testosterone and dihydrotestosterone from binding to the receptor. CPA also lowers serum levels of gonadotropins LH and FSH. Further, 21-hydroxylase is also inhibited by CPA so that synthesis of mineral corticoids (e.g., aldosterone) or glucocorticoids (e.g., cortisol) is inhibited. There are positive reports regarding use of CPA in HS ^[23][38][39]. In a randomized trial, CPA has been compared with norgestrel ^[38]. There was no significant difference between the two groups. Both drugs showed a similar response.

Table 5. Use of cyproterone acetate (CPA, competitive antagonist at the androgen receptor) in HS.

Flutamide has a non-steroidal anti-androgenic effect. One case report reports an improvement in HS under flutamide with a dose of 250 mg daily ^[40]. The antidiabetic drug metformin has a mild anti-androgenic effect and is used in PCOS. The data on metformin and HS are listed in the subsection on insulin resistance and adipokines.

3.4. Insulin Resistance and Adipokines

5. Insulin Resistance and Adipokines

An association between HS and metabolic syndrome has been reported in several studies ^[41]. Truncal obesity, hypertension, diabetes mellitus type II, and dyslipoproteinemia, characteristics of metabolic syndrome, are frequently found in HS patients. Metabolic syndrome is present in 32.4% of HS patients ^[42]. A recent meta-analysis estimated the pool ratio of metabolic syndrome in HS to be 2.66 (95% CI: 1.90-3.72) ^[43]. There is also an association between HS and diabetes mellitus ^[44][45]. A meta-analysis showed that there is a 1.69-fold increased risk of developing diabetes mellitus in HS ^[46]. A cross-sectional analysis in the United States showed an overall prevalence of 24.8% for type 2 diabetes mellitus in HS ^[47]. In the same cohort, the prevalence of type 2 diabetes mellitus in non-HS patients was 15.6%. In a comparative cross-sectional study of 3207 patients, a significant association was presented between HS and metabolic syndrome [odds ratio (OR) 1.61, 95% confidence interval (CI) 1.36-1.89], diabetes mellitus (OR 1.41, 95% CI 1.19-1.66), obesity (OR 1.71, 95% CI 1.53-1.91), hyperlipidemia (OR 1.14, 95% CI 1.02-1.28), and hypertension (OR 1.19, 95% CI 1.03-1.38) ^[48]. Many patients have impaired glucose tolerance. The exact mechanism of impaired tolerance is not clear.

There is some research on adipokine levels in HS (Table 6). Adipokines are signaling molecules produced by adipose tissue. They act as a link between the immune system and energy metabolism. With weight gain, the pro-inflammatory effect increases, and, with hunger, the anti-inflammatory effect increases. Known adipokines include plasminogen activator inhibitor-1 (PAI-1), leptin, visfatin, adiponectin, apelin, interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), retinol binding protein 4 (RBP4), TNF-α, omentin-1, and vaspin. Secretion and expression of adipokines is disturbed in cardiovascular diseases and obesity ^[49]. In a case-control study by Malara et al., the adipokines adiponectin, resistin, and leptin in blood were compared to healthy controls, nondiabetic obese group, and psoriasis patients ^[50]. The mean serum levels of adiponectin were significantly decreased in patients with HS compared to healthy lean controls, and the resistin and leptin levels were increased [50]. In all the patient groups, BMI and serum levels of leptin (r=0.83) and resistin (r=0.6) were strongly correlated. The authors suggested that serum levels of adipokines are dysregulated in HS and are associated with obesity ^[50]. Expression of adipokines in this study was shifted towards pro-inflammatory resistin and leptin. Akdogan et al. found that serum levels of visfatin after adjustment for BMI and smoking status differed significantly (P = 0.02) and increased the risk of HS 1.56-fold ^[51]. González-López also reports that visfatin and resistin are independent risk factors for HS [52]. Both adipokines were independent of age, sex, and body mass index. Adiponectin was inversely associated with IR (OR 0.994; CI 95%, 0.989-0.999; p = 0.023) and resistin positively (OR 1.012; CI 95%, 1.001-1.024; p = 0.03) after adjustment (age, sex, BMI, and smoking status) [52]. However, there seems to be no correlation between serum levels of adipokines and severity of HS ^[52]. Another adipokine is retinol binding protein 4 (RBP4), which is produced by fat cells ^[53]. RBP4 is elevated in insulin resistance and also in diabetes mellitus ^[54][55]. RBP4 is also a transport protein for free vitamin A ^[56]. In a cross-sectional study of 137 patients (77 HS patients and 60 controls) without diabetes mellitus, higher RBP4 and lower ghrelin levels were found in HS ^[57]. RBP4 levels correlated positively with disease severity and insulin resistance in HS patients independent of BMI ^[57]. There was no correlation between disease severity and ghrelin. Omentin-1 was also found to be elevated in HS patients compared to healthy controls after adjustment for BMI, age, and sex ^[58]. Omentin-1 is an adipocytokine expressed in visceral fat. Omentin-1 has an important role in body metabolism and insulin sensitivity via AMP-activated protein kinase ^[59].

Increased incidence of insulin resistance in HS also suggests a disturbed hormonal axis ^[42][51][60]. Insulin resistance has often been determined by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). HOMA-IR is calculated from the product of fasting insulin (µu/ml) and fasting blood glucose (mg/dl), which is then divided by 405 ^[61]. A HOMA-IR value above 2.5 may indicate insulin resistance. In a cross-sectional and case-control study, 76 patients with HS and 61 age- and sex-matched control subjects have been compared for the presence of insulin resistance ^[60]. The median HOMA-IR value was significantly higher in HS than in controls (2.0 vs. 1.5; p = 0.01) ^[60]. Prevalence of IR was also significantly higher than in controls (43.4% vs. 16.4%; p = 0.001) [60]. The authors, therefore, recommend that HS patients should be screened for IR. The study by Akdogan et al. and Özkur et al. also showed a significant correlation between HS and insulin serum levels [42,51]. Weight loss in HS patients has a positive effect on insulin resistance and can lead to a decrease in HS lesions and insulin resistance ^[62]. This supports the central role of insulin resistance in HS (Figure 21).

Table 6. Current findings about adipokines and insulin resistance in HS.

1. ^{[87][63][64][65][66][67][68][69][70][71][72][73][74][75][76][}

^13]. There are hardly any data available on sex hormone progesterone in HS. As some patients demonstrate a link between HS and pregnancy, further investigation of progesterone levels during pregnancy and after pregnancy might be useful. Peripubertal onset of HS, premenstrual deterioration, and postpartum deterioration supported the role of sex hormones in HS ^[7][11][12]. However, this connection has not yet been proven. A subdivision between hormone-dependent and hormone-dependent HS could be interesting in the future to provide further information, as well as that cross-sex hormone therapy worsens HS, showing that androgens should be considered in HS pathogenesis ^[18][19].

Insulin resistance is present in between 43.4 and 45.9% of HS patients, which is higher than healthy controls ^[42][60]. In a cross-sectional and case-control study, IR was significantly increased in HS patients compared to healthy controls (43.4% vs. 16.4%, p = 0.001) [60]. Almost half of the patients had insulin resistance according to the data. For this reason, testing for IR in HS patients is useful to detect possible diabetes mellitus at an early stage. This could prevent secondary diseases from diabetes mellitus and metabolic syndrome. Cardiovascular risk factors are significantly more common in HS patients, as also indicated by a significant increase in systemic immune-inflammation-based biomarkers ^[78][79]. For this reason, typical cardiovascular risk factors should be screened for. The exact mechanism of IR should be investigated in future studies to better understand HS. Antidiabetic therapy with metformin resulted in clinical improvement in 50%–72% of HS patients ^[63][64][65]. Metformin therapy in HS was well-tolerated. Most common side effects were gastrointestinal symptoms. Metformin causes increased insulin sensitivity and highlights the role of insulin resistance in HS. The results of the double-blind, randomized metformin trial will provide new insights into the hormonal role in HS. It remains to be seen whether HS patients with insulin resistance respond better to metformin therapy. In a case report, a positive effect of liraglutide on HS has been reported. Liraglutide is a GLP-1 analogue and is used in diabetes mellitus. High weight loss and bariatric surgery in HS patients lead to clinical improvement in HS ^[80]. This supports the fact that impaired glucose tolerance must be considered in HS therapy. Diet also proves beneficial for HS ^[81]. Ramadan fasting is a well-known diet and provides increased insulin sensitivity^[82][83]. A multicenter, observational cross-over pilot study about Ramadan fasting in HS showed significant improvement in IHS4 ^[81]. Fasting has an impact on adipokine release ^[84]. The literature clearly indicates that adipokine balance is disturbed in HS. It is shifted towards pro-inflammatory adipokines. The anti-inflammatory adipokine adiponectin is decreased in HS ^[50][52]. Pro-inflammatory adipokines visfatin, resistin, omentin-1, and RBP4 are elevated in HS. A disbalance in adipokines could lead to impairment in regulation of fat storage glucose tolerance and insulin release ^[85]. Authors also discuss obesity-induced inflammation in HS, which has an impact on insulin signaling ^[43].

Thyroid disease and PCOS are also more commonly associated with HS. Both hyperthyroidism and hypothyroidism have been described. The frequent occurrence of thyroid diseases in HS could be related to the smoking behavior of HS patients ^{[36][44][70][71]}. Autoimmunity of the thyroid gland is not more common in HS patients ^[40][69][74]. There is no new research examining the hypothalamic–pituitary axis. However, the current data do not allow any clear conclusions to be drawn about thyroid function in HS. HS with vulva involvement was significantly associated with thyroid disease ^[72]. The reasons for this association are unknown. PCOS is also common in HS and should be considered if typical symptoms are present. PCOS is characterized by hyperinsulinemia, reduced insulin sensitivity, and hyperandrogenism. Increased insulin causes increased synthesis of androgen in the ovary and adrenal cortex. Other HS patients without PCOS and with insulin resistance could have a similar pathway.

5. Conclusions

Overall, there is some evidence that hormones play an important role in HS. However, there is still a lack of randomized controlled trials and experimental studies investigating the influence of hormones in HS. A double-blind randomized metformin trial will provide the first meaningful findings. The influence of insulin resistance on the HS pathomechanisms is currently still underestimated. Future studies should investigate function of adipokines and insulin resistance in HS. A decoupled axis between insulin metabolism, immune system, and hormonal axis could be an important starting point for further HS research.

Informationion: The article is based on a publication by Abu Rached et al. 2022.^[86]

References

1. ^{[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62]77][78][79][80][81][82][83][84][85]}

Metformin is an oral antidiabetic drug that increases the effect of insulin. The insulin sensitizer has the effect of reducing glucose production in liver and increasing glucose utilization by muscle and fat cells. Metformin also has an anti-inflammatory effect on several cell types. It has been reported by Chung et al. that metformin reduces production of nitric oxide (NO), prostaglandin E2 (PGE2), and pro-inflammatory cytokines, such as IL-6, IL-1β and TNF-α [63]. This is probably reduced by inhibiting activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) in macrophages. A therapeutic response of metformin in HS patients has already been described in the literature (Table 7). In a prospective study (n=25) with metformin, 72% of the patients experienced clinical improvement in HS ^[63]. DLQI also improved in 64% of the patients. In a retrospective study of children with HS, response to therapy was 50% of the patients ^[64]. In Jennings’ study, most patients on metformin therapy have been analyzed so far ^[65]. The study showed a treatment response of 68 %. In 19% of the patients, use of metformin led to complete remission. It was interesting to note that 75% of the patients had insulin resistance ^[65]. Overall, metformin has been well-tolerated by patients. The most common side effect was gastrointestinal symptoms ^[63][64][65]. The effect of metformin on HS is currently being investigated in the first double-blind randomized trial called “Rediscovery of Metformin in Chronic Invalidating Autoinflammatory Disease Hidradenitis Suppurativa” (ClinicalTrials.gov Identifier: NCT04649502). The primary endpoint of the metformin study is clinical response, assessed by IHS4. Secondary endpoints include insulin resistance, lesion count, pain, HS-PGA, cost-effectiveness, change in biomarker calprotectin, relapses, treatment satisfaction, DLQI, safety, and tolerability. In the first study arm, patients receive metformin and doxycycline. In the placebo arm, patients receive placebo and doxycycline. The first results of the metformin trial are expected in 2023.

Another antidiabetic drug is liraglutide. There is only one case report of clinical experience with liraglutide in HS ^[66][67]. Liraglutide is a GLP-1 agonist and directly stimulates GLP-1 receptor. Stimulation of GLP-1 results in glucose-dependent insulin secretion and inhibition of glucagon secretion. As with metformin, most common side effects of liraglutide include gastrointestinal symptoms. In rare cases, pancreatitis and pancreatic carcinoma can occur. After four weeks of liraglutide therapy, an obese patient who was not insulin-resistant experienced clinical improvement in HS and DLQI ^[66]. HS-PGA decreased from 4 to 1 and DLQI from 24 to 14 under liraglutide.

Table 7. Current findings about antidiabetic drugs metformin (enhancement of the insulin effect) and liraglutide (Glucagon-like Peptide-1 agonist, GLP-1 agonist) in HS.

Figure 21. Schematic diagram with relationship between insulin resistance, adipokines, and HS.

3.5. Thyroid Function in HS

6. Thyroid Function in HS

The thyroid gland also plays an important role in human hormone balance. In the thyroid gland, iodine-containing hormones including triiodothyronine (T3) and thyroxine (T4) are produced by thyrocytes. Both hormones are important in metabolic process and growth. T3 is biologically more active than T4 and is produced from T4 by type 1 and 2 deiodinases. Thyroid hormones act on many organs. In general, two hormones have an increasing effect on energy metabolism. Thyroid hormones affect the heart by increasing expression of β-receptors and heart rate ^[68]. In metabolism, they increase basal metabolic rate and oxygen consumption. Glucose absorption, gluconeogenesis, and glycogen synthesis are increased. Regulation of the thyroid gland takes place via the hypothalamus–pituitary axis. Thyroid-stimulating hormone (TSH) from the pituitary gland is released after stimulation by thyrotropin-releasing hormone (TRH) from the hypothalamus. TSH stimulates T3 and T4 synthesis. In hyperthyroidism, there is increased production of the hormones. Patients complain of tachycardia, weight loss, increased body temperature, tremor, sleep disturbances, and high nervousness. In hypothyroidism, patients have bradycardia, weight gain, decreased body temperature, fatigue, and dry skin. In addition, the hormone calcitonin is produced in the C-cells of the thyroid gland. Calcitonin is mainly involved in calcium balance and lowers short-term calcium in the blood.

Large case-control studies and cohort studies have shown that thyroid disease is a common comorbidity of HS (Table 8) ^[44][69]. Liakou et al. described that severity of HS was significantly correlated with presence of thyroid disease and active smoking ^[70]. In a population-based cross-sectional study of 4191 people, the association between HS and thyroid disease has been investigated ^[71]. There was an increased odds ratio for hypothyroidism (OR 2.91; 95% CI: 2.48-3.40; p<0.001) and hyperthyroidism (OR 2.25; 95% CI: 1.55-3.28; p<0.001) in HS compared to controls. The association between HS and hypothyroidism was also confirmed via multivariate logistic regression analysis. Even after controlling for age, sex, socioeconomic status, and smoking, the association remained significant. The association between HS and hyperthyroidism was not significant in the adjusted model, so HS was only independently significant with hypothyroidism. In contrast to the results of Sherman et al., the study by Miller et al. showed a significant correlation between HS and increased TSH and decreased free T3 ^[36][71]. Miller et al. retrospectively examined blood of 430 HS patients for thyroid hormones. Clinical hyperthyroidism was also significantly associated after removal of confounding factors (OR of 1.91; 95% CI 1.19-3.07; p=0.02) ^[36]. HS with vulvar involvement (VHS) is also associated with thyroid disease. López-Llunell et al. studied 25 patients with VHS and found that patients had late onset of disease. The average BMI of VHS was normal (HS with VHS: 23.2 kg/m2 vs. HS without: VHS 28.6 kg/m2) ^[72]. A nationwide cohort analysis in Denmark investigated medication of HS patients ^[73]. No increased hazard ratio for thyroid medication could be found. The authors assume that comorbidities such as thyroid disease occur in severe courses ^[73]. Gonzoalez-Lopez et al. also reported that thyroid function parameters did not differ between HS patients and controls ^[74]. Autoimmune antibodies against the thyroid gland also do not differ significantly between HS and non-HS patients ^[45][74].

Table 8. Current findings about thyroid function in HS. 

7. Polycystic Ovary Syndrome (PCOS) and HS

3.6. Polycystic Ovary Syndrome (PCOS) and HS

Another comorbidity of HS in women is also polycystic ovary syndrome (PCOS). PCOS is an endocrine disorder characterized by hyperandrogenism, cycle disorder, and, less commonly, polycystic ovaries. Many patients demonstrate a phenotype of metabolic syndrome. Pathophysiologically, insulin resistance is present, leading to increased androgen synthesis by IGF-1 in the ovary. Hyperandrogenemia leads to virilization and LH dominance. Patients with PCOS may receive anti-androgenic therapy with metformin or oral contraceptives. The prevalence of PCOS in HS is 9% according to available data. In a meta-analysis with five case-control studies, HS patients were shown to have a 2.64-fold greater risk of PCOS (Table 9) ^[75]. Screening for PCOS can be useful in certain patients.

Table 9. Current findings on PCOS and HS.

4. Discussion

The role of hormones in HS seems to be complex due to many hormonal feedbacks. Data on sex hormones in HS are controversial, suggesting that androgens are involved in pathogenesis of female HS patients. It is interesting to note that, in female HS patients, genes controlled by androgens are upregulated ^[13][16]. In formen, it seems that androgens play a subordinate role in HS. An investigation of androgens with clinical classification into three subtypes, axillary-mammary, follicular, and gluteal, could be useful for further insights ^[77]. In Mortimer and coworkers’ study, 88.1% of the patients were of the follicular type and had significantly elevated testosterone ^[17]. In another study by Harrison et al., no increased testosterone was found, but it is not clear from the data which clinical phenotype was present in these patients ^[20]. The follicular type of HS shows similarities to acne vulgaris so that increased androgen would be a plausible explanation. To be able to assess this conclusively, clinical phenotyping in further studies is required. It might be useful to investigate whether the follicular type of HS responds better to antiandrogenic therapy than other subtypes. The response to antiandrogenic therapy in women may be related to the segmental AR expression pattern of the skin tunnels ^[13]. For this reason, it may be useful to investigate the clinical response to antiandrogenic therapy with the AR expression pattern in females. Routine immunohistochemical AR staining could become a tool to extend HS therapy. Antiandrogenic therapy is a good option according to the available data for female patients. The clinical response in HS of spironolactone and finasteride ranged from approximately 40% to 85% ^{[5][25][27][35]}. Overall, both drugs are tolerated and few side effects have been reported. Antiandrogenic therapy should not be used in male patients as there is little experience, and it could have more severe side effects. Estrogen does not seem to play a role in pathogenesis of HS ^[